Montelucast-Teva (montelukast sodium) chewing tablets 5 mg. №28


Montelucast is used for the treatment of adults, as a drug for the additional treatment of bronchial asthma in patients with persistent asthma, both mild and moderate, including those who are not sufficiently controlled by inhaled GCS.



Montelucast composition
active substance: montelukast sodium;
1 tablet contains 5.2 mg montelukast sodium, which corresponds to 5.0 mg montelukast;
excipients: mannitol (E 421), microcrystalline cellulose, low-substituted hydroxypropyl cellulose, croscarmellose sodium, aspartame (E 951), cherry flavor, magnesium stearate, iron oxide red (E 172).

Dosage form
Chewable tablets.

Pharmacological properties
Montelucast belongs to the group of cystenyl-leukotriene receptor blockers, which play an important role in the development of broncho-obstructive syndrome.
As a result, the drug is effective in the treatment of obstructive diseases that develop in the lower parts of the respiratory system.
Montelukast, which is the main active ingredient of the drug, has the property, when applied, to bind to cystenyl-leukotriene receptors (CysLT1 receptors), which are responsible for the occurrence of bronchospasm, sputum secretion from the bronchi, and other symptoms accompanying obstructive bronchitis.
Capable of inhibiting bronchoconstriction in patients with asthma.
It has the property of arresting the arising bronchospasm at all stages of its development, due to the ability to reduce the body’s response to allergic antigens.
The use of montelukast leads to a decrease in the number of eosinophils in the airways.

Montelucast is used for the treatment of adults, as a drug for the adjunctive treatment of bronchial asthma in patients with persistent asthma, both mild and moderate, including those who are insufficiently controlled by inhaled GCS.
Also effective if the patient shows insufficient asthma control with short-acting β-agonists.
Also applicable for:

  • symptomatic treatment of seasonal allergic rhinitis in patients with bronchial asthma;
  • prevention of asthma, in which bronchospasm is provoked by physical exertion;
  • relieve symptoms of seasonal and perennial allergic rhinitis.

You should not use the specified drug if the patient has had a previous hypersensitivity (allergy) with respect to one of the components that are part of the drug – both main and auxiliary.

For use in children from 6 to 14 years old. Children over the age of 15 should take 10 mg montelukast tablets.

Application during pregnancy and lactation
Treatment of pregnant women is carried out with every possible care, only for serious indications.
Breastfeeding should be suspended during treatment.

Method of administration and dosage
Montelucast should be used by children under adult supervision.
Patients with bronchial asthma and allergic rhinitis (seasonal and year-round) need to take 1 chewable tablet 5 mg once a day. To relieve the symptoms of allergic rhinitis, the time of admission should be selected individually.
For the treatment of bronchial asthma, the dose for children from 6 to 14 years old is 1 chewable tablet (5 mg) once a day, in the evening, 1 hour before or 2 hours after a meal. No dose adjustment is necessary for this age group.
Adults and children from 15 years of age should take 10 mg montelukast tablets.

Overdose with this drug does not cause any particular adverse events. In rare cases, the following were observed:

  • drowsiness, psychomotor hyperactivity;
  • thirst;
  • headache;
  • vomiting.

Symptomatic therapy is recommended.

Side effects
The drug is usually well tolerated. Side effects can occur only in rare cases. In particular, there may be observed:

  • anaphylactic reactions, hypersensitivity reactions, including anaphylactic shock;
  • upper respiratory tract infections;
  • headache, abdominal pain, thirst, nausea, vomiting, dyspepsia;
  • increased bleeding;
  • sleep disturbances, nightmares, hallucinations, insomnia, irritability, anger, agitation, hostility, depression, disorientation, suicidal thoughts;
  • lethargy, dizziness, paresthesia, hypersthesia, palpitations;
  • hepatitis, increased levels of hepatic transaminases;
  • arthralgia, myalgia, including muscle cramps;
  • asthenia / fatigue, discomfort, swelling, fever;
  • nose bleed.

Storage conditions and periods
Montelucast is able to maintain its medicinal properties for 2 years from the date of manufacture indicated on the package.
The drug should be kept out of the reach of children. Storage temperature should not exceed 25 ° C.